M&A activity, IPOs and late-stage investments gain momentum as investors prioritize clinical validation, while early-stage biotech firms continue to face funding challenges
The company hosted Symbiosis 2026 at its 2-acre manufacturing facility in Bengaluru, inaugurated in 2024
Veteran health innovation and policy leader to drive biotechnology innovation, startup growth and commercialization of indigenous technologies
The new facility will produce precision extruded medical tubing used in minimally invasive medical devices
The collaboration is focused on overcoming a major limitation in existing cancer drugs
New Tracxn report highlights growing investor confidence in automated cell therapy production, with Cellares and Ori Biotech dominating funding and regulatory milestones
New AMF Series combines industry-leading 1000:1 turndown capability, predictive diagnostics, and digital connectivity in a footprint no larger than a standard Post-it Note pad
.jpeg)
One of our major priorities in next 3-5 years is the introduction of a kit-based version of CanAssist Breast, enabling hospitals conduct the test locally
Industry veteran with over two decades of experience to lead expansion across India, South Asia, Southeast Asia, and other high-growth healthcare markets
As per the Department of Pharmaceuticals, the sector has expanded its reach across the country while strengthening domestic production capabilities and innovation
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
